PGABFProstatype Genomics AB

About Prostatype Genomics AB (PGABF)

Prostatype Genomics AB (PGABF) is a N/A company headquartered in Nacka Strand, Sweden whose shares trade over-the-counter on the OTCQB tier.

Prostatype Genomics AB (the "Company") is a public company registered in Sweden founded in 2007 with a mission to turn research findings into clinical applications. Originally a spin-off from Cancer Center Karolinska (Karolinska Institute, Stockholm, Sweden), 15 years of dedicated research on prostate cancer genomics has culminated in the development of the Prostatype gene test which is now clinically validated and available on the market. Our mission is to elevate the quality of life and provide peace of mind to those battling prostate cancer and our vision is to empower doctors and patients with unwavering confidence in their treatment decisions.

Products and services

The company's product is a gene test specially designed for patients with localized prostate cancer, helping patients and healthcare professionals make well-informed treatment decisions. By providing a personalized assessment of cancer aggressiveness, the test can significantly reduce the over and under-treatment, which enhances the quality of life but also saves valuable resources for the healthcare industry.

PGABF key facts

Ticker symbol

PGABF

Market tier

OTCQB

Headquarters

Nacka Strand, Sweden

Country of incorporation

SE

Year of incorporation

2007

Employees

6

Estimated market cap

$2.45M (as of May 13, 2025)

Shares outstanding

6,835,213

Reporting standard

International Reporting: NASDAQ Stockholm

Audit status

Audited

Fiscal year end

12/31

Latest filing

Interim Financial Report (Dec 31, 2024)

Prostatype Genomics AB leadership

• Fredrik Rickman — CEO
• Anders Koch — CFO
• Gerald Andriole — CMO
• Emelie Berglund — CTO

Explore more: OTCQB stocks · OTC stocks starting with P